EyeGate Pharma Announces That EGP-437 Improved Signs And Symptoms Of Dry Eye Syndrome In A Phase II Study
Based on the top-level analysis of a Phase II study, EyeGate Pharma announces that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, improved signs and symptoms in patients with dry eye syndrome (DES). For the dry eye clinical trial, EyeGate worked with Ora, Inc., a leading global clinical research and development organization located in Andover, MA.
More: continued here
Filed under: Clinical Trials on June 5th, 2009
You must be logged in to post a comment.